These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

841 related items for PubMed ID: 27018175

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
    Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M.
    Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.
    Lancet; 2016 Jul 02; 388(10039):31-44. PubMed ID: 27130691
    [Abstract] [Full Text] [Related]

  • 7. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
    Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S.
    Lancet Respir Med; 2015 May 02; 3(5):355-66. PubMed ID: 25736990
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X.
    Curr Med Res Opin; 2017 Sep 02; 33(9):1605-1613. PubMed ID: 28644104
    [Abstract] [Full Text] [Related]

  • 13. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.
    Lancet Respir Med; 2014 Nov 02; 2(11):879-890. PubMed ID: 25306557
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
    Li J, Wang F, Lin C, Du J, Xiao B, Du C, Sun J.
    J Asthma; 2017 Apr 02; 54(3):300-307. PubMed ID: 27435534
    [Abstract] [Full Text] [Related]

  • 15. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 02; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
    Carr WW, McDonald M, Meizlik P.
    Allergy Asthma Proc; 2019 Jul 01; 40(4):240-249. PubMed ID: 31262379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M.
    J Allergy Clin Immunol Pract; 2019 Feb 01; 7(2):589-596.e3. PubMed ID: 30193936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.